Please note that slides are for review only and not to be repurposed or published.

PART 1 — MANAGEMENT OF EARLY AND ADVANCED PROSTATE CANCER

MODULE 1:
Available and Emerging Biomarkers to Inform Decision-Making for Patients with Early-Stage Prostate Cancer (PC) and Use of Active Surveillance — Dr Concepcion

MODULE 2:
Optimal Integration of Chemotherapy into the Management of Endocrine-Sensitive Metastatic PC — Dr Lin

MODULE 3:
Sequence and Selection of Systemic Therapy for Patients with mCRPC — Dr Quinn

MODULE 4:
Role of Bone-Targeted Therapies Across the PC Continuum — Dr Sartor

MODULE 5:
Ongoing Investigation and Potential Integration of Secondary Hormonal Therapy, Immunotherapy or Cytotoxic Therapy into the Management of Earlier-Stage Disease — Dr Gomella

PART 2 — ROLE OF IMMUNE CHECKPOINT INHIBITORS IN THE MANAGEMENT OF BLADDER CANCER

MODULE 1:
Current Urothelial Bladder Cancer (UBC) Management Approaches and the Integration of Immune Checkpoint Inhibitors — Dr Daneshmand

MODULE 2:
Principles of Cancer Immunotherapy; Practical Considerations with the Use of Immune Checkpoint Inhibitors — Dr Drake

MODULE 3:
Overview of and Current Indications for the Use of Immune Checkpoint Inhibitors in UBC — Dr Rosenberg

MODULE 4:
Incidence and Management of Unique Toxicities Associated with Checkpoint Inhibitors; Autoimmune Contraindications to Treatment — Dr Plimack

MODULE 5:
Ongoing Clinical Research with Immune Checkpoint Inhibitors in UBC — Dr Svatek